Cearnal Martin E's Form 4 filing
Cumberland Pharmaceuticals Inc (CPIX) · filed Jan 7, 2022
- Accession no.
- 0001209191-22-002447
- Filed
- Jan 7, 2022
- Trade date
- Dec 1-20, 2021
- Filing delay
- 37 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 14 non-derivative transactions. Open-market purchases total $9.57K. It was filed 37 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cearnal Martin ECIK 0001408500 | Director, Officer (Sr VP/Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 1, 2021 | Common Stock | PPurchaseAcquired | +90 | $4.14 | +$372.6 | 176,449 | Direct | |
| Dec 2, 2021 | Common Stock | PPurchaseAcquired | +90 | $3.84 | +$345.6 | 176,539 | Direct | |
| Dec 3, 2021 | Common Stock | PPurchaseAcquired | +90 | $4.47 | +$402.3 | 176,629 | Direct | |
| Dec 6, 2021 | Common Stock | PPurchaseAcquired | +90 | $4.46 | +$401.4 | 176,719 | Direct | |
| Dec 7, 2021 | Common Stock | PPurchaseAcquired | +90 | $5.61 | +$504.9 | 176,809 | Direct | |
| Dec 8, 2021 | Common Stock | PPurchaseAcquired | +90 | $6.15 | +$553.5 | 176,899 | Direct | |
| Dec 9, 2021 | Common Stock | PPurchaseAcquired | +90 | $5.81 | +$522.9 | 176,989 | Direct | |
| Dec 10, 2021 | Common Stock | PPurchaseAcquired | +90 | $4.82 | +$433.8 | 177,079 | Direct | |
| Dec 13, 2021 | Common Stock | PPurchaseAcquired | +200 | $4.36 | +$872 | 177,279 | Direct | |
| Dec 14, 2021 | Common Stock | PPurchaseAcquired | +200 | $4.28 | +$856 | 177,479 | Direct | |
| Dec 15, 2021 | Common Stock | PPurchaseAcquired | +200 | $4.29 | +$858 | 177,679 | Direct | |
| Dec 16, 2021 | Common Stock | PPurchaseAcquired | +240 | $4.53 | +$1,087.2 | 177,919 | Direct | |
| Dec 17, 2021 | Common Stock | PPurchaseAcquired | +240 | $4.17 | +$1,000.8 | 178,159 | Direct | |
| Dec 20, 2021 | Common Stock | PPurchaseAcquired | +314 | $4.33 | +$1,359.62 | 178,473 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.